Market-based policies the biopharmaceutical industry supports that can lower patients’ drug costs.
AstraZeneca Plc Chief Executive Officer Pascal Soriot discusses drug pricing.
Eli Lilly & Co. CEO discusses drug pricing and trade tariffs.
U.S. Health and Human Services Secretary Alex Azar discusses Donald Trump's plans to lower drug prices and overhaul the pharmaceutical industry.
Novo Nordisk CEO Lars Fruergaard Jorgensen discusses challenges facing the drug industry, the U.S. healthcare system and Brexit.
There remains a great deal of interest in how drugs are priced.